NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Longer Term Trading Plans for NTLA. Buy NTLA near 10.06 target 13.33 stop loss @ 10.03 Details; The technical summary data ...
Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also ...
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO Capital Markets from $70.00 to $50.00 in a research report issued to clients and ...
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...
In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique ...
Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...
In October, Intellia Therapeutics reported drug study progress ... On January 9, 2025, the company announced it would discontinue efforts on NTLA-3001, one of its pipeline gene-editing treatments.